Interim report
INTERIM REPORT 1 JANUARY - 30 SEPTEMBER 1998 * Operating income increased to SEK 46.6 (20.3) million. * Net loss for the period amounted to SEK -15.7 (-33.2). * Liquid funds and short-term investments amounted to SEK 209 million, compared to SEK 127.0 million on 31 December 1997. * The collaboration projects with Bristol-Myers Squibb (BMS) and Merck & Co (Merck) are advancing positively and according to plan. * Important results in the Company's project for the treatment of type 2 diabetes have been achieved. Additional trials strengthen Karo Bio's project. KARO BIO AB Novum, Hälsovägen 7,